FOXO3 and breast carcinoma: In the current study, we found that DNMT1-mediated FOXO3a promoter hypermethylation leads to downregulation of FOXO3a expression in breast cancer, and FOXO3a suppresses BCSC properties and tumorigenicity via inhibition of FOXM1/SOX2 signaling.